Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TWINSS Extension Trial of Iscalimab in Sjögren's Syndrome
jRCT2071200072Completed
- Sponsor
- Novartis
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label trial of iscalimab in Sjögren's syndrome (2 arms), sponsored by Novartis. Primary endpoints: Incidence of Treatment-emergent AEs (TEAEs), Change in laboratory evaluations for hematology and 2 more. Started Oct 2019; status: completed.
02
Drugs
iscalimab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on jRCT2071200072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200072.